Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
  • Op-Ed
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Awards
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
    • Women in Healthcare
    • - Luminaries
    • - Top 25 Diversity Leaders
    • - Leaders to Watch
    • - Luminaries
    • - Top 25 Women Leaders
    • - Women to Watch
  • Events
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Custom Media Event: ESG Summit
    • Transformation Summit
    • Women Leaders in Healthcare Conference
    • Social Determinants of Health Symposium
    • Leadership Symposium
    • Health Care Hall of Fame Gala
    • Top 25 Women Leaders Gala
    • Best Places to Work Awards Gala
    • Top 25 Diversity Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain Revenue Cycle
    • - Hospital at Home
    • - Workplace of the Future
    • - Strategic Marketing
    • - Virtual Health
  • Listen
    • Podcast - Next Up
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
October 21, 2014 01:00 AM

Reform Update: Medicaid programs crafting limits on Harvoni usage

Virgil Dickson
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    Which Medicaid beneficiaries will have access to Gilead Sciences' newest high-cost hepatitis C treatment, Harvoni, and when they'll get that access, now depends on prior-authorization criteria being hammered out by various state agencies.

    Most will likely limit Harvoni use to patients dealing with liver failure, as 35 states now do for Gilead's Sovaldi. Some may adopt restrictions such as banning those dealing with drug and alcohol addiction from getting the specialty drug, or limiting who may prescribe it to only board-certified gastroenterologists, hepatologists or infectious disease physicians. Another option is implementing the so-called “once in a lifetime” rule, which allows Medicaid patients only one chance at treatment.

    Federal regulation stipulates Medicaid agencies must cover Food and Drug Administration-approved drugs marketed by companies that have negotiated rebates with the federal Medicaid drug-rebate program. Gilead participates in that program. Federal law also allows states the discretion of implementing prior-authorization criteria as they see fit.

    Related Content

    Gilead Sciences gets go-ahead for Harvoni, its second high-priced hepatitis C drug

    Harvoni was approved by the FDA Oct. 10. It costs $94,500 for a 12-week regimen. Gilead's hepatitis C drug Sovaldi costs $1,000 a pill, or $84,000, for a 12-week regimen. However, Gilead argues that Harvoni can be a bargain considering that it costs $63,000 for an eight-week regimen and as many as 45% of patients may qualify for the shorter treatment duration.

    Compliance to a treatment regimen may be higher with Harvoni than it is with Sovaldi. That's because Harvoni is the first single-pill hepatitis C treatment. Sovaldi requires intravenous treatment with interferon or ribavirin, which are known to have side effects including flu-like symptoms, experts say.

    In addition, clinical trials for Harvoni found that over 94% to 99% of the patients treated with the drug had no detectable virus in their blood three months after treatment was ended. This compared with 82% to 90% nondetectable rates in clinical trials of Sovaldi plus interferon and ribavirin.

    Despite claims of better price, fewer side effects and higher efficacy rates, it is unlikely states will make Harvoni their preferred hepatitis C drug over Sovaldi and will likely move forward covering both drugs simultaneously, experts say. One reason is that not everyone agrees with Gilead's assertion that Harvoni is more affordable.

    “The older drugs used in combination with Sovaldi are very inexpensive to the Medicaid program due to large available rebates, so the cost of the interferon and the ribavirin is negligible,” a spokeswoman from the Minnesota Department of Human Services said. As a result, “the Sovaldi combination is still less expensive than the single-pill Harvoni regimen, at least for the Medicaid program.”

    Another reason is that the drugs differ in terms of effectiveness for various strains of hepatitis C. There are six different genotypes of the virus. Harvoni is shown to be best for genotype 1, believed to be the most common strain, while Sovaldi is believed to be best for genotypes 2 and 3, according to Nancy Steinfurth, executive director of Hep C Connection, an advocacy and awareness organization.

    As a result, Washington state will only cover Harvoni for those with genotype 1, a spokeswoman there said. Idaho is following a similar course of action, developing prior-authorization criteria that require a beneficiary to have documented proof that clinical need is not met by Sovaldi.

    Medicaid agency spokespeople from Ohio, New Mexico and Texas say their agencies have yet to make decisions on what authorization criteria they'll use. None revealed a timeline to make a decision. Texas is also believed to be only state in the U.S. to not provide coverage in any fashion for Sovaldi, having yet to craft prior-authorization criteria for its use there.

    Oregon has a unique waiver that allows it to not cover drugs, even if the manufacturer has an agreement with the federal Medicaid drug rebate program. It attempted to exercise this authority earlier this summer to not cover Sovaldi, but advocates were successful in stopping the state from taking the action. Instead Oregon created a prior-authorization criteria for the drug for the 10% of Medicaid beneficiaries in the state's fee-for-service program, and left it up to coordinated-care organizations that care for the other 90% to come up with their own prior-authorization policies for the drug. A similar course of action is expected for Harvoni, an Oregon Health Authority spokeswoman said.

    For the vast majority of their Medicaid populations, states such as Hawaii and Pennsylvania are following Oregon's lead, leaving prior-authorization policies for Harvoni to their managed Medicaid providers. There are 37 states that in varying degrees use managed-care organizations to provide services to beneficiaries. Of those, 28 states include pharmacy benefits in their contracts.

    Spokespeople from Iowa, Florida, Georgia, Minnesota, Montana, Nebraska, Nevada, South Dakota and Virginia, said they don't expect a prior-authorization policy to be developed for Harvoni until spring 2015 when their pharmacy and therapeutics committees or drug utilization review boards again convene to look into the drug's clinical benefit. Until then, some will allow access to the drug on a case-by-case basis, depending on documented medical necessity.

    Alaska, Idaho, Tennessee and Oklahoma are now covering the drug with prior authorization, though the current pre-approval criteria may be later updated as they learn more about the drug, spokespeople from those states said.

    In Mississippi, if Harvoni is administered in a physician's office, prior authorization is not required, said Erin Barham, deputy administrator for communications for Medicaid.

    “Although this particular drug treatment for hepatitis C can be expensive, in a majority of cases it has a high potential of curing the disease if prescribed and taken correctly, resulting in a positive impact on beneficiaries and the state budget in the long run,” Barham said.

    CMS: Medicaid enrollment continues to increase

    Medicaid enrollment reached 67.9 million in August, up 8.7 million people since before ACA open enrollment in October 2013, a CMS report says (PDF).

    That represents a nearly 15% increase over the average monthly enrollment of July to September of last year. Enrollment in states that expanded Medicaid grew by 22%, compared to just 5% in states that did not.

    Treasury: Income drop will not require subsidy repayment

    A person who qualified for subsidies on the health insurance marketplace and then saw their income drop below the poverty level will not have to pay back the premium tax credits they've received.

    According to a Treasury Department rule, if the insurance marketplace estimates that someone's income will be between 100% and 400% of poverty and it turns out that his income for the year is below the poverty threshold, the individual won't be on the hook for any premium tax credits they received.

    Follow Virgil Dickson on Twitter: @MHvdickson

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Ezike 800.jpg
    Former Illinois health chief Ezike under scrutiny by state's top ethics investigator
    AHRQ Director Robert Valdez in front of American flag
    Q&A: AHRQ chief aims to help communities improve their health systems
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2022. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Op-Ed
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Awards
      • Nominate/Eligibility
      • 100 Most Influential People
      • 50 Most Influential Clinical Executives
      • Best Places to Work in Healthcare
      • Excellence in Governance
      • Health Care Hall of Fame
      • Healthcare Marketing Impact Awards
      • Top 25 Emerging Leaders
      • Top 25 Innovators
      • Diversity in Healthcare
        • - Luminaries
        • - Top 25 Diversity Leaders
        • - Leaders to Watch
      • Women in Healthcare
        • - Luminaries
        • - Top 25 Women Leaders
        • - Women to Watch
    • Events
      • Conferences
        • Transformation Summit
        • Women Leaders in Healthcare Conference
        • Social Determinants of Health Symposium
        • Leadership Symposium
      • Galas
        • Health Care Hall of Fame Gala
        • Top 25 Women Leaders Gala
        • Best Places to Work Awards Gala
        • Top 25 Diversity Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain Revenue Cycle
        • - Hospital at Home
        • - Workplace of the Future
        • - Strategic Marketing
        • - Virtual Health
      • Webinars
      • Custom Media Event: ESG Summit
    • Listen
      • Podcast - Next Up
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing